NFKB1 and metabolic dysfunction-associated steatotic liver disease: Therefore, inhibiting NF-κB activation and reducing the expression of TNF-α and IRS-1Ser307 phosphorylation were of great significance for the prevention and treatment of NAFLD insulin resistance.